Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than that in the group of participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-12, Vol.385 (26), p.2485-2487
Hauptverfasser: Baden, Lindsey R, El Sahly, Hana M, Essink, Brandon, Follmann, Dean, Neuzil, Kathleen M, August, Allison, Clouting, Heather, Fortier, Gabrielle, Deng, Weiping, Han, Shu, Zhao, Xiaoping, Leav, Brett, Talarico, Carla, Girard, Bethany, Paila, Yamuna D, Tomassini, Joanne E, Schödel, Florian, Pajon, Rolando, Zhou, Honghong, Das, Rituparna, Miller, Jacqueline
Format: Artikel
Sprache:eng
Schlagworte:
Age groups
Coronavirus
Coronaviruses
Correspondence
COVID-19
COVID-19 vaccines
HIV
Human immunodeficiency virus
Infectious Disease
Infectious diseases
Medical research
mRNA
R&D
Research & development
Severe acute respiratory syndrome coronavirus 2
Vaccine efficacy
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than that in the group of participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy over time.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2115597